US 12,280,061 B2
Optimised dosage of diaminophenothiazines in populations
Claude Michel Wischik, Aberdeen (GB); Björn Olaf Schelter, Aberdeen (GB); and Helen Christine Shiells, Aberdeen (GB)
Assigned to WisTa Laboratories Ltd., Singapore (SG)
Appl. No. 17/262,902
Filed by WisTa Laboratories Ltd., Singapore (SG)
PCT Filed Jul. 18, 2019, PCT No. PCT/EP2019/069428
§ 371(c)(1), (2) Date Jan. 25, 2021,
PCT Pub. No. WO2020/020751, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 1812193 (GB), filed on Jul. 26, 2018; and application No. 1909458 (GB), filed on Jul. 1, 2019.
Prior Publication US 2021/0236509 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A23L 33/00 (2016.01); A23L 33/105 (2016.01); A23L 33/15 (2016.01); A23L 33/175 (2016.01); A23L 33/29 (2016.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/13 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/5415 (2013.01) [A23L 33/105 (2016.08); A23L 33/15 (2016.08); A23L 33/175 (2016.08); A23L 33/29 (2016.08); A23L 33/30 (2016.08); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/13 (2013.01); A61P 25/28 (2018.01)] 20 Claims
 
1. A method of therapeutic treatment of a neurodegenerative disorder of protein aggregation in a human subject,
which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
wherein said administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day, optionally split into 2 or more doses,
wherein the MT-containing compound is LMTM:

OG Complex Work Unit Chemistry
and
wherein said neurodegenerative disorder is Alzheimer's disease.